M. Hubert

发表

Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects

R. Capdeville, B. Peng, A. Bolton, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic and Pharmacodynamic Assessments of HMG‐CoA Reductase Inhibitors When Coadministered with Everolimus

J. Kovarik, Stefan Hartmann, C. Rordorf, 2002, Journal of clinical pharmacology.

Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.

A. Oza, E. Rubin, M. Hubert, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of Effects of Terbinafine on Single Oral Dose Pharmacokinetics and Anticoagulant Actions of Warfarin in Healthy Volunteers

M. Hubert, P. Francheteau, M. Guerret, 1997, Pharmacotherapy.

Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.

E. Legangneux, M. Hubert, S. Appel‐Dingemanse, 1999, British journal of clinical pharmacology.

STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake.

Michael Stumm, Kristian Pietras, C. Heldin, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules

R. Capdeville, B. Peng, M. Hubert, 2004, Cancer Chemotherapy and Pharmacology.

Effect of zinc on the treatment of Plasmodium falciparum malaria in children: a randomized controlled trial.

W. Fawzi, Z. Premji, D. Hamer, 2002, The American journal of clinical nutrition.

The Effects of Tegaserod (HTF 919) on the Pharmacokinetics and Pharmacodynamics of Digoxin in Healthy Subjects

Honghui Zhou, M. Hubert, J. McLeod, 2001, Journal of clinical pharmacology.

Steady‐state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol® XL

M. Hubert, Denise Barilla, P. Prasad, 2004, Biopharmaceutics & drug disposition.

First Pharmacokinetic—Pharmacodynamic Study in Humans with a Selective 5‐Hydroxytryptamine4 Receptor Agonist

M. Hubert, T. Duvauchelle, A. Kumle, 1997, Journal of clinical pharmacology.

Tegaserod (HTF 919) does not decrease the effectiveness of an oral contraceptive when coadministered to healthy female subjects

Honghui Zhou, M. Hubert, Peiming Ma, 2000 .

Tegaserod Pharmacokinetics Are Similar in Patients with Severe Renal Insufficiency and in Healthy Subjects

S. Swan, Honghui Zhou, M. Hubert, 2003, Journal of clinical pharmacology.

Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope

G. Cheymol, M. Hubert, M. Guerret, 2004, European Journal of Clinical Pharmacology.